Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 21794948)

Published in J Am Acad Dermatol on July 26, 2011

Authors

Theo M Starink1, Arjan C Houweling, Martijn B A van Doorn, Edward M Leter, Elisabeth H Jaspars, R Jeroen A van Moorselaar, Piet E Postmus, Paul C Johannesma, Jan Hein van Waesberghe, Martijn H Ploeger, Marieke T Kramer, Johan J P Gille, Quinten Waisfisz, Fred H Menko

Author Affiliations

1: Birt-Hogg-Dubé Working Group, Department of Dermatology, VU University Medical Centre, Amsterdam, The Netherlands. thm.starink@vumc.nl

Articles by these authors

Biallelic inactivation of BRCA2 in Fanconi anemia. Science (2002) 9.31

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet (2005) 4.92

A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet (2003) 4.79

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81

Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81

Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol (2012) 3.28

Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 3.10

Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res (2003) 3.02

Roberts syndrome is caused by mutations in ESCO2, a human homolog of yeast ECO1 that is essential for the establishment of sister chromatid cohesion. Nat Genet (2005) 2.77

Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59

Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.52

Identification of the Fanconi anemia complementation group I gene, FANCI. Cell Oncol (2007) 2.50

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45

Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res (2005) 2.41

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13

External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol (2008) 2.13

Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol (2006) 2.12

Exome sequencing reveals mutated SLC19A3 in patients with an early-infantile, lethal encephalopathy. Brain (2013) 2.09

Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up study. Circulation (2011) 2.04

Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res (2005) 1.94

Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum (2002) 1.91

Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology (2008) 1.79

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77

Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood (2003) 1.71

Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. Eur Heart J Cardiovasc Imaging (2012) 1.66

PLS3 mutations in X-linked osteoporosis with fractures. N Engl J Med (2013) 1.66

Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology (2004) 1.62

Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax (2012) 1.59

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol (2007) 1.58

Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol (2003) 1.58

TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet (2010) 1.54

Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer (2004) 1.49

The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology (2004) 1.41

Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology (2005) 1.39

Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation (2013) 1.35

Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of Dutch genome diagnostic laboratories. Hum Mutat (2013) 1.32

Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. BMC Med Genet (2006) 1.29

Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res (2003) 1.23

Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys (2002) 1.23

Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer (2007) 1.21

Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families. J Invest Dermatol (2007) 1.21

High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat (2007) 1.16

Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiother Oncol (2003) 1.15

Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res (2005) 1.15

Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J Clin Invest (2010) 1.13

Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12

The cellular phenotype of Roberts syndrome fibroblasts as revealed by ectopic expression of ESCO2. PLoS One (2009) 1.08

Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat (2011) 1.07

Arrhythmogenic right ventricular dysplasia/cardiomyopathy diagnostic task force criteria: impact of new task force criteria. Circ Arrhythm Electrophysiol (2010) 1.07

Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer (2003) 1.07

MLC1: a novel protein in distal astroglial processes. J Neuropathol Exp Neurol (2005) 1.05

Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol (2003) 1.05

Reflecting on earlier experiences with unsolicited findings: points to consider for next-generation sequencing and informed consent in diagnostics. Hum Mutat (2013) 1.04

Birt-Hogg-Dube syndrome is a novel ciliopathy. Hum Mol Genet (2013) 1.04

A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. Cancer Epidemiol Biomarkers Prev (2014) 1.03

A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. Hum Mutat (2010) 1.02

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet (2011) 1.01

Atrial and ventricular myosin heavy-chain expression in the developing chicken heart: strengths and limitations of non-radioactive in situ hybridization. J Histochem Cytochem (2006) 1.00

A homozygous MSH6 mutation in a child with café-au-lait spots, oligodendroglioma and rectal cancer. Fam Cancer (2004) 1.00

The Fanconi anemia gene product FANCF is a flexible adaptor protein. J Biol Chem (2004) 1.00

Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer. Breast Cancer Res Treat (2009) 1.00

Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma (2008) 0.98

Non-invasive prenatal detection of achondroplasia in size-fractionated cell-free DNA by MALDI-TOF MS assay. Prenat Diagn (2007) 0.98

Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer. J Med Genet (2010) 0.97

Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet (2011) 0.97

Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance. Fam Cancer (2012) 0.96

Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol (2003) 0.96

Informing family members about a hereditary predisposition to cancer: attitudes and practices among clinical geneticists. J Med Ethics (2010) 0.95

Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer (2006) 0.95

Diaphragm muscle fiber weakness in pulmonary hypertension. Am J Respir Crit Care Med (2010) 0.95

Next-generation sequencing-based genome diagnostics across clinical genetics centers: implementation choices and their effects. Eur J Hum Genet (2015) 0.94

Colorectal cancer risk variants on 11q23 and 15q13 are associated with unexplained adenomatous polyposis. J Med Genet (2013) 0.94

Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2004) 0.94

Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int (2008) 0.94

Colorectal cancer in the family: psychosocial distress and social issues in the years following genetic counselling. Hered Cancer Clin Pract (2007) 0.93

A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations. Genes Chromosomes Cancer (2005) 0.93

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics (2012) 0.93

Distinct regulation of developmental and heart disease-induced atrial natriuretic factor expression by two separate distal sequences. Circ Res (2008) 0.92

Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result. Psychooncology (2010) 0.91

Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol (2010) 0.90

Mutations in RARS cause hypomyelination. Ann Neurol (2014) 0.90

Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol (2007) 0.89